Abstract:Background BRD7 is a tumor suppressor known to inhibit cell proliferation and cell cycle progression and initiate apoptosis in breast cancer. However, the function and underlying molecular events of BRD7 in tumor invasion and metastasis in breast cancer are not fully understood. Methods BRD7 expression was assessed in two stable cell lines MDA231 and MCF7 with BRD7 overexpression and one stable cell line MDA231 with BRD7 interference using qRT-PCR and western blotting. CCK8 assay was used to examine the proliferation ability of MDA231 and MCF7 cells. Scratch wound healing assay was used to evaluate cell migration in MDA231 and MCF7 cells. Both Matrigel and three-dimensional invasion assays were performed to investigate the cell invasion ability after BRD7 overexpression or silencing or YB1 restoration in MDA231 and MCF7 cells. The potential interacting proteins of BRD7 were screened using co-immunoprecipitation combined with mass spectrometry and verified by co-immunoprecipitation in HEK293T cells. Additionally, we confirmed the specific binding region between BRD7 and YB1 in HEK293T cells by constructing a series of deletion mutants of BRD7 and YB1 respectively. Finally, xenograft and metastatic mouse models using MDA231 cells were established to confirm the effect of BRD7 on tumor growth and metastasis. Results Here, the results of a series of assays in vitro indicated that BRD7 has the ability to inhibit the mobility, migration and invasion of breast cancer cells. In addition, YB1 was identified as a novel interacting protein of BRD7, and BRD7 was found to associate with the C-terminus of YB1 via its N-terminus. BRD7 decreases the expression of YB1 through negatively regulating YB1 phosphorylation at Ser102, thereby promoting its proteasomal degradation. Furthermore, gene set enrichment analysis revealed that epithelial-mesenchymal transition (EMT) is the common change occurring with altered expression of either BRD7 or YB1 and that BRD7 represses mesenchymal genes and activates epithelial genes. Moreover, restoring the expression of YB1 antagonized the inhibitory effect of BRD7 on tumorigenicity, EMT, invasiveness and metastasis through a series of in vitro and in vivo experiments. Additionally, BRD7 expression was negatively correlated with the level of YB1 in breast cancer patients. The combination of low BRD7 and high YB1 expression was significantly associated with poor prognosis, distant metastasis and advanced TNM stage. Conclusions Collectively, these findings uncover that BRD7 blocks tumor growth, migration and metastasis by negatively regulating YB1-induced EMT, providing new insights into the mechanism by which BRD7 contributes to the progression and metastasis of breast cancer.

Tumor suppressor bromodomain-containing protein 7 cooperates with Smads to promote transforming growth factor-β responses

BRD7 Suppresses Tumor Chemosensitivity to CHK1 Inhibitors by Inhibiting USP1-mediated Deubiquitination of CHK1

BRD7 Stabilizes P53 via Dephosphorylation of MDM2 to Inhibit Tumor Growth in Breast Cancer Harboring Wild-type P53

The transcriptional regulation role of BRD7 by binding to acetylated histone through bromodomain

WDR74 Functions As a Novel Coactivator in TGF-β Signaling.

BRD7 Inhibits the Warburg Effect and Tumor Progression Through Inactivation of HIF1α/LDHA Axis in Breast Cancer

Smad7: Not Only a Regulator, but Also a Cross-Talk Mediator of TGF-β Signalling

Smad7 antagonizes transforming growth factor β signaling in the nucleus by interfering with functional Smad-DNA complex formation

BRD7 Suppresses Invasion and Metastasis in Breast Cancer by Negatively Regulating YB1-induced Epithelial-Mesenchymal Transition

Integrating ChIP-sequencing and Digital Gene Expression Profiling to Identify BRD7 Downstream Genes and Construct Their Regulating Network

BRD7, a novel bromodomain gene, inhibits G1-S progression by transcriptionally regulating some important molecules involved in ras/MEK/ERK and Rb/E2F pathways.

Smad7 Enables STAT3 Activation and Promotes Pluripotency Independent of TGF-β Signaling

Smad7 Protein Interacts with Receptor-regulated Smads (R-Smads) to Inhibit Transforming Growth Factor-β (TGF-β)/Smad Signaling

Regulation of TGF- signaling by Smad7

BRD7 Plays an Anti-Inflammatory Role During Early Acute Inflammation by Inhibiting Activation of the NF-кB Signaling Pathway.

Study the motif-bromodomain of BRD7 and identify a novel interaction protein with BRD7

BRD7, a Novel Bromodomain Gene, Inhibits G1–S Progression by Transcriptionally Regulating Some Important Molecules Involved in Ras/mek/erk and Rb/E2F Pathways

BRD7 Promotes Cell Proliferation and Tumor Growth Through Stabilization of c-Myc in Colorectal Cancer

Analysis of Bromodomain of BRD-7 Gene and Its Prokaryotic Expression.

Transcriptional regulation of BRD7 expression by Sp1 and c-Myc